Patent ID: 9546355
Date: 2017-01-17
CPC Classifications: A61K,A61P,C12N

Claim:
1. An immunogenic composition comprising an immunologically effective amount of a conditional replication defective cytomegalovirus (CMV) and a pharmaceutically acceptable carrier, wherein the conditional replication defective CMV comprises: (a) a pentameric gH complex comprising UL128, UL130, UL131, gH and gL; and (b) a nucleic acid encoding a first fusion protein between IE1/2 and a destabilizing protein and a second fusion protein between UL51 and the destabilizing protein, wherein the destabilizing protein is FK506-binding protein (FKBP) derivative comprising amino acid substitutions F36V and L106P; wherein the wild type IE1/2 and UL51 are no longer present and wherein the CMV is an attenuated strain that has restored gH complex expression due to a repair of a mutation in the UL131 gene.